A detailed history of China Universal Asset Management Co., Ltd. transactions in Arcellx, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 10,339 shares of ACLX stock, worth $781,008. This represents 0.1% of its overall portfolio holdings.

Number of Shares
10,339
Previous 6,287 64.45%
Holding current value
$781,008
Previous $346,000 149.42%
% of portfolio
0.1%
Previous 0.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$50.91 - $86.61 $206,287 - $350,943
4,052 Added 64.45%
10,339 $863,000
Q2 2024

Jul 19, 2024

SELL
$49.74 - $66.98 $193,488 - $260,552
-3,890 Reduced 38.22%
6,287 $346,000
Q1 2024

Apr 29, 2024

BUY
$51.85 - $73.49 $235,658 - $334,012
4,545 Added 80.7%
10,177 $708,000
Q4 2023

May 21, 2024

SELL
$31.75 - $57.99 $144,303 - $263,564
-4,545 Reduced 44.66%
5,632 $312,000
Q4 2023

Jan 23, 2024

BUY
$31.75 - $57.99 $139,192 - $254,228
4,384 Added 351.28%
5,632 $313,000
Q3 2023

May 21, 2024

BUY
$31.51 - $37.4 $19,504 - $23,150
619 Added 98.41%
1,248 $44,000
Q3 2023

Oct 30, 2023

BUY
$31.51 - $37.4 $19,504 - $23,150
619 Added 98.41%
1,248 $45,000
Q2 2023

May 21, 2024

BUY
$27.49 - $46.9 $962 - $1,641
35 Added 5.89%
629 $19,000
Q2 2023

Jul 27, 2023

BUY
$27.49 - $46.9 $962 - $1,641
35 Added 5.89%
629 $20,000
Q1 2023

May 21, 2024

BUY
$26.92 - $33.94 $4,011 - $5,057
149 Added 33.48%
594 $18,000
Q1 2023

Apr 27, 2023

BUY
$26.92 - $33.94 $4,011 - $5,057
149 Added 33.48%
594 $18,000
Q4 2022

May 21, 2024

SELL
$17.18 - $33.0 $167,195 - $321,156
-9,732 Reduced 95.63%
445 $13,000
Q4 2022

Jan 31, 2023

BUY
$17.18 - $33.0 $7,645 - $14,685
445 New
445 $14,000

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.31B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.